All News

One of the highlights of #EULAR2026 for me: ♀️The "This Is a Woman's World" session I recapped 8 must-know abstracts (including our work from ARCH_ArLAR) in a new @RheumNow video🎬 https://t.co/3jwJIegGg4 via @YouTube @ArLARheumatolog https://t.co/Azvkl2sjdu

Failure to achieve early remission RA asso w/ non-inflammatory pain NORD-STAR 526 early RA pts) no remission at 24 wks increased risk of 48wk • unacceptable pain (OR ~6) • refractory pain (OR ~6) • fibromyalgic RA (OR ~16) Signal strongest w/ very early remission wk8 https://t.co/H8iyhIrsJw

https://x.com/AurelieRheumo/status/2062950853187695084/photo/1

Even with tight T2T, ARCTIC 10yr follow-up (n=170) show 9% had RA-ILD on HRCT, plus another 19% with non-specific interstitial findings. Male sex and older age were risk factors. Seropositivity was not. Vigilance remains essential. @RheumNow #EULAR2026 POS1270

Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA? Over 70% of patients with psoriatic arthritis (PsA) struggle with excess weight, amplifying synovio-entheseal inflammation and blunting biologic response. https://t.co/pAIXkdazci https://t.co/vQTn3BWv2r

Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA? | RheumNow

CT imaging in RA Body composition changes beyond BMI 489 RA vs 397 ctrl RA asso w/ -increased subcutaneous fat -increased intermuscular adipose tissue -poorer muscle quality Looks like it represent “hidden obesity” with more by fat redistribution and myosteatosis #OP0348

And now does MRI do better than US at predicting RA progression in at risk pts? Short answer: No likely too sensitive! 130 anti-CCP+ symptomatic pts 36.9% progressed BL US positivity predicted progression HR 2.8 MRI showed prevalence of subclinical disease synovitis >80%

Detecting subclinica tenosynovitis in pts at risk for RA: who does it better US or DixonMRI? 65 pts RA CSA, US detected only ~23% of cases identified by Dixon US misses most! But are they “real” tenosynovitis? MRI (5-min, no contrast) higher sens US higher spe Shall we do https://t.co/stsMRdj9eY

https://x.com/AurelieRheumo/status/2062946900035203290/photo/1

#EULAR2026 POS0172 #Lupus arthritis is the most common domain in RCTs but SLEDAI-MSK or BILAG-MSK isn’t satisfactory. Look out for the role out of LAMDA once externally validated using independent trial datasets. 4 candidates: SJC28, ESR, VAS Phy MSK, & VAS Pa Pain @RheumNow https://t.co/QJ51ETLSSN

https://x.com/Yuz6Yusof/status/2062889577862344849/photo/1

Lung US for RA-ILD screening Comparison with diagnostic scores 147 RA pts (68 ILD on HRCT) Asymptomatic cohort Sens 95.4% Spe 77.7% Risk scores alone performed poorly. Combining US + risk scores boosted sensitivity to 100% → promising low-cost screening tool alongside HRCT. https://t.co/7C4zClaxry

https://x.com/AurelieRheumo/status/2062945697104617940/photo/1

Can AI read 20 years of RA X-rays? And how much faster/better than us? 20 years ESPOIR cohort 7500+ joints RADAR algorithm 94–95% accuracy compared with expert readers 99% spe 93% sens #OP0344 #EULAR2026 @RheumNow https://t.co/8hFHCY4SaY

https://x.com/AurelieRheumo/status/2062944529456521501/photo/1

Can AI spot RA inflammation from a thermal hand scan? Cohort 100 RA pts AI model analysing thermal images detected US PD+ wrist inflammation AUC 0.87 Main features wrist temperature & heat-pattern With all due validation could this be the next mass screening tool for RA? https://t.co/2AzXj5yQJI

https://x.com/AurelieRheumo/status/2062926841321496811/photo/1

A biomarker for CV disease in RA? Anti-CXCR3 antibodies asso w/ atherosclerosis Confirmed in a validation cohort Adding Ab profile to the mSCORE increases AUC from 0.6 to 0.9 Sens from 30 to 69% How does it compare with other ways of detecting atherosclerosis? #POS0899 https://t.co/O7bsLrVyzo

How to treat #RA-#ILD Similar to #IPF Occurs older men esp Smoking risk Vaccines Etc Philippe Dieude #HOT #EULAR2026 @RheumNow https://t.co/F4h9daSLhF

https://x.com/Janetbirdope/status/2062914666938896727/photo/1

Which b/tsDMARDs are effective in #axSpA? Stratified by extramusculoskeletal manifestations Check out the latest update of the treatment heatmap 🔥 By Astrid van Tubergen At axial and peripheral SpA at a crossroads session #EULAR2026 @RheumNow https://t.co/uTxEJqbDBm

https://x.com/Nellziade/status/2062912494360813829/photo/1

Controversial #Rheumatoid #arthritis disease activity May not affect #ILD BUT affects #mortality level evidence +/- PHillippe Dieude said #Rx from RCTs #IS Ex #rituximab #antifibrotics #nintedanib #nerandomilast HOw to Treat RA-ILD June 5 #EULAR2026 @RheumNow @eular_ARD https://t.co/R60nX6XzL8

What b/ts DMARDs are effective and not effective in axSpA? Prof. Astrid van Tubergen presents this very informative summary slide summarizing treatment in axSpA. @RheumNow #EULAR2026 https://t.co/5udGPB1Hrr

Not all #RA pts respond equally to advanced therapy. 10-variable risk model >18k US pts: low baseline disease activity, fewer comorbidities, and no prior biologics 5x more likely to achieve remission at 1yr (34% vs 7%). RWD for precision care @RheumNow #EULAR2026 POS0257

Can we finally personalize MTX dosing in #RA? liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay (n=59): MTX-PG3 levels ↑ with dose and age, ↓ with higher disease activity and concomitant biologics. Route (oral vs SC) didn't matter. @RheumNow #EULAR2026 POS0251

Gecacitinib (pan-JAK inhibitor) vs placebo in radiographic #axSpA ASAS40 51.9% vs 12.9% (p<0.0001) at 16 weeks. ASAS20 69.2% vs 21.2% (p<0.0001). Pan-JAK inhibition showed efficacy in TNFi-experienced patients. Abstr OP0240 @RheumNow #EULAR2026

ETA+MTX vs triple therapy after MTX failure in #RA: machine learning-emulated RACAT trial (n=3,472 VA pts) confirms ETA+MTX modestly better overall. But smoking matters: benefit disappears in current smokers. Precision medicine from RWD. @RheumNow #EULAR2026 POS0255

Topics

All News

Do you get our email newsletter?